Aerovate Therapeutics, Inc. (AVTE)
After hours:
- GlobeNewswire
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHCT continues at more than 120 sites globally WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today pre
- GlobeNewswire
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Enrollment continues into the Phase 3 portion of the IMPAHCT trial of AV-101 Poster to be presented with baseline characteristics of the Phase 2b portion of the IMPAHCT trial at the ATS 2024 Conference on May 21 Cash runway into 2026, based on our current operating plan WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeu
- GuruFocus.com
Aerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 Shares
Timothy Noyes, the Chief Executive Officer of Aerovate Therapeutics Inc (NASDAQ:AVTE), sold 10,000 shares of the company on April 1, 2024, according to a recent SEC Filing.
